Charterhouse enters Italian market, buys Doc Generici

Doc Generici has been sold by three pharmaceutical groups: Canada-based Apotex and Italy's Chiesi Farmaceutici and Zambon.

The deal value remains undisclosed but is reported to stand at around 2.5x the company's turnover, which reached around €132m in 2012. The debt to equity split is believed to stand at around 50-50, with debt provided by HSBC and Intesa San Paolo.

Company
Doc Generici was founded in 1996 by pharmaceutical groups Apotex, Chiesi Farmaceutici and Zambon.

Distribution began in 2001, after the approval of a law that meant pharmacists were obliged to provide an equivalent medicine at the lowest price available when a doctor did not specify that the prescribed medicine could not be substituted.

In 2012 the firm reported revenues of €132m, with EBITDA reaching €43m.

People
Gordon Bonnyman is executive chairman of Charterhouse.

Advisers
Equity – Chiomenti Studio Legale (Legal); Jefferies (Corporate finance).
Vendor – Rothschild (Corporate finance); Freshfields (Legal).
Management - NCTM Studio Legale Associato (Legal).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Southern Europe
• Healthcare
• Buyouts
• Italy
• Charterhouse Capital Partners